In September, Karnataka Food Safety and Drug Administration seized medicines from two Amazon-linked facilities for storing drugs without a licence, raising questions about regulatory clarity in India's e-pharmacy sector, according to medianama.com. The seizures highlight the challenges in applying the Drugs and Cosmetics Act, 1940, to modern online medicine sales, where inventory ownership and storage are often separated among multiple entities.
India's drug law requires any entity selling, stocking, or distributing drugs to hold a licence tied to specific premises and to have a registered pharmacist or competent person in charge. This framework assumes the seller also holds the inventory, which fits traditional chemist shops. However, in online sales, the licensed seller, marketplace, warehouse, and delivery operator can be distinct, complicating compliance. The Karnataka FDA's action targets this gap, as Amazon's facilities were storing medicines without the required licence, per medianama.com.
The issue matters because it determines who bears responsibility for drug safety, prescription compliance, and authenticity in e-pharmacy transactions. With the rise of online medicine sales, the existing law's premise of a single licensed entity holding inventory is outdated. The Karnataka seizures underscore the need for regulatory clarity to address the roles of warehouses and marketplaces in digital drug supply chains, a concern echoed in ongoing policy discussions.
The Drugs and Cosmetics Rules, 1945, specify retail and wholesale licences (Form 20, 21, 20B, 21B) attached to premises, but do not explicitly address inventory held by third-party warehouses. The Karnataka FDA's recent enforcement action is the most prominent case highlighting this legal ambiguity in India’s e-pharmacy regulation, as reported by medianama.com.